Top Cited Papers
Open Access
- 31 July 2022
- journal article
- review article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (9) , 3707-3728
Abstract
Melasma is a common malady affecting all races with a higher incidence in Hispanics, Middle Eastern, Asians, and African origin females (Fitzpatrick skin phototypes III–V). Women are affected much more often than men. Melasma remains a significant cause of cosmetic morbidity and psychosocial embarrassment affecting quality of life necessitating effective and reliable treatment. Unfortunately, treatment remains unsatisfactory due to limited efficacy, adverse effects, and relapses after stopping treatment. Although chemical peels, laser and light therapies and dermabrasion may have utility, the evidence available for their efficacy is limited and they often cause post‐inflammatory hyperpigmentation, particularly in individuals with darker skin types. Medical therapies remain mainstay in the management of melasma. The triple combination, hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01% (Triluma, Galderma, Ft. Worth Texas, often modified incorporating different corticosteroids) remains the only US FDA‐approved treatment for melasma and is the gold standard due its demonstrated efficacy across ethnicities. Oral tranexamic acid alone or in combination with other modalities has also shown significant efficacy. Several cosmeceuticals and botanical extracts used as skin lightening agents have been demonstrated to be useful. Physical sunscreens containing zinc oxide, iron oxide, titanium dioxide, and silicones provide photoprotective and camouflage effect. We propose that a multimodality approach to the treatment of melasma is the most effective treatment approach. This review is focused on the medical therapies for melasma.Keywords
This publication has 129 references indexed in Scilit:
- Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laserEuropean Journal of Medical Research, 2013
- Successful treatment of hydroquinone-resistant melasma using topical methimazoleDermatologic Therapy, 2013
- Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trialJournal of Cosmetic and Laser Therapy, 2012
- Plasmin Inhibitors Prevent Leukocyte Accumulation and Remodeling Events in the Postischemic MicrovasculaturePLOS ONE, 2011
- A randomized, double‐blind, placebo‐controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino womenInternational Journal of Dermatology, 2009
- Efficacy of dioic acid compared with hydroquinone in the treatment of melasmaInternational Journal of Dermatology, 2009
- Topical treatment of melasmaIndian Journal of Dermatology, 2009
- The prevalence of melasma and its association with quality of life in adult male Latino migrant workersInternational Journal of Dermatology, 2008
- A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 001, hydroquinone 4, tretinoin 005) compared with hydroquinone 4 cream in Asian patients with moderate to severe melasmaBritish Journal of Dermatology, 2008
- Intravenous vitamin C in the treatment of post‐laser hyperpigmentation for melasma: A short reportJournal of Cosmetic and Laser Therapy, 2008